Log in with your email address username.

×

[Correspondence] Checkpoint blockade therapy resistance in Hodgkin’s lymphoma

About 50 years ago, the enigma of Hodgkin’s lymphoma was depicted as the Hodgkin maze in two editorials in The Lancet.1,2 The uncertainties of the time were expressed through two questions: “Infection or neoplasm?” and “One entity or two (or more)?”.2 Subsequently, advances in cell biology and molecular pathology provided answers to these questions. Substantial evidence now indicates that classical Hodgkin’s lymphoma is a distinct neoplastic entity, with heterogeneous pathological features, which might be associated with Epstein-Barr virus infection.

email